BIOTECHNOLOGY

Rhinomed’s Mute is fastest growing nasal strip in US

Finfeed Archived Jul 11, 2019

Rhinomed Ltd (ASX:RNO), are leaders in airway technology and the developers of the Mute nasal stent, the fastest growing product in the nasal strip category in US based drug stores.

Star Combo surges on Bio-E acquisition

Finfeed Archived Jul 08, 2019

Leading distributor and manufacturer of branded premium health and natural beauty products, Star Combo Pharma Ltd (ASX:S66) has made a transformational acquisition of Bio-e.

Alcidion signs key contract with NSW Health

Finfeed Archived May 20, 2019

Alcidion Group (ASX:ALC) will build and integrate two key components for a proposed national Child Digital Health Record (CDHR), thanks to a new contract with NSW Health.

Digestive health supplement lifts Immuron’s sales

Finfeed Archived Apr 15, 2019

Immuron Limited (ASX:IMC | NASDAQ:IMRN) third quarter sales for its commercially available products, including Travelan®, surged 66%.

Ellume, the digital diagnostics company helping people beat the flu

Finfeed Archived Apr 12, 2019

Dr Sean Parsons is the founder of Ellume, an emerging digital diagnostics company situated in Brisbane that provides smart, self-use diagnostics for the detection and management of pandemic influenza.

Immuron seeking FDA approval for travelers’ diarrhea drug candidate

Finfeed Archived Apr 11, 2019

Australian biopharmaceutical company, Immuron Limited (ASX: IMC |NASDAQ: IMRN), plans to pursue clinical development of IMM-124E, its bovine polyclonal antibody drug candidate to prevent travelers’ diarrhea, through a formal FDA registration pathway.

Genetic Technologies teams up with TGen

Finfeed Archived Apr 08, 2019

Genetic Technologies Ltd (ASX:GTG), a provider of world-leading genetic risk assessment test products, has established an important MoU with TGen, a major player in the US biomedical research industry.

Imugene to present cancer vaccine programs to the American Association for Cancer Research

Finfeed Archived Mar 04, 2019

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic will present on its KEYVaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

Cashed up Imugene to present at American Association for Cancer Research

Finfeed Archived Feb 28, 2019

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors.

One emerging industry could be the next investment opportunity

Finfeed Archived Feb 19, 2019

Global biotech company Zoono Group Limited (ASX:ZNO) Founder and CEO Paul Hyslop is an expert on long lasting antimicrobial protection and outlines the industry opportunity to The Capital Network’s Executive Director Lelde Smits.

Hemp demand sees Elixinol fly high with outstanding revenue growth

Finfeed Archived Feb 19, 2019

Shares in Elixinol Global Ltd (ASX:EXL; OTCQX:ELLXF) have surged in February after the company announced outstanding year-on-year revenue growth for both the December quarter and calendar year 2018.

PTX is one step closer to finding a working cancer treatment

Finfeed Archived Jan 29, 2019

Prescient Therapeutics (ASX:PTX) CEO Steven Yatomi-Clarke speaks with Finfeed about the latest results in the company's cancer treatment trials.

I’m dreaming of a genome Christmas

Finfeed Archived Jan 29, 2019

CRISPR-Cas9 is a gene editing tool that makes it easier to edit the genome. It has become so popular among the research and development set that companies.

These Israeli tech stocks are winning the market-disruption game, part 2

Finfeed Archived Jan 24, 2019

Yesterday, we outlined five ASX-listed Israeli tech stocks that are standing out. Here's another five to keep an eye on.

These Israeli tech stocks are winning the market-disruption game, part 1

Finfeed Archived Jan 23, 2019

There are now some 17 Israel-born companies on the ASX, most of which are small caps, playing in a diverse range of tech-heavy markets, from telecommunications and digital media through to innovations in agriculture and legalised weed. We have scoped out 10 you should keep an eye on, and are starting with the following five.

Biotechnology